GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cara Therapeutics Inc (STU:69C) » Definitions » Sale Of Investment

Cara Therapeutics (STU:69C) Sale Of Investment : €104.73 Mil (TTM As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Cara Therapeutics Sale Of Investment?

Cara Therapeutics's sale of investment for the three months ended in Sep. 2024 was €2.25 Mil. It means Cara Therapeutics gained €2.25 Mil from selling investments. Cara Therapeutics's sale of investment for the trailing twelve months (TTM) ended in Sep. 2024 was €104.73 Mil.

Compared with last quarter (€14.40 Mil in Jun. 2024 ), Cara Therapeutics gained less money from selling investments in Sep. 2024 (€2.25 Mil).


Cara Therapeutics Sale Of Investment Historical Data

The historical data trend for Cara Therapeutics's Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cara Therapeutics Sale Of Investment Chart

Cara Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sale Of Investment
Get a 7-Day Free Trial Premium Member Only Premium Member Only 230.03 175.05 180.55 211.87 146.21

Cara Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Sale Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 43.41 33.79 54.28 14.40 2.25

Cara Therapeutics Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.

Sale Of Investment for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €104.73 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cara Therapeutics Sale Of Investment Related Terms

Thank you for viewing the detailed overview of Cara Therapeutics's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.


Cara Therapeutics Business Description

Traded in Other Exchanges
Address
400 Atlantic Street, Suite 500, Stamford, CT, USA, 06901
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.

Cara Therapeutics Headlines

No Headlines